Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited)

v3.20.1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Gain (loss) [Member]
Accumulated Deficit [Member]
Series A Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Total
Balance, at beginning at Dec. 31, 2018   $ 212,157 $ (41) $ (188,452)     $ 23,664
Balance, at beginning (in shares) at Dec. 31, 2018 328,689       9,856    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock upon conversion of Series A Convertible preferred stock $ 1 (1)          
Issuance of common stock upon conversion of Series A Convertible preferred stock (in shares) 281,610       (9,856)    
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per share)   70         70
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per share) (in shares) 2,000            
Employee stock purchase plan   3         3
Employee stock purchase plan (in shares) 177            
Stock-based compensation   305         305
Foreign currency translation gain     2       2
Net loss       (6,233)     (6,233)
Balance, at end at Mar. 31, 2019 $ 1 212,534 (39) (194,685)     17,811
Balance, at end (in shares) at Mar. 31, 2019 612,476            
Balance, at beginning at Dec. 31, 2019 $ 9 226,524 (46) (217,070)     9,417
Balance, at beginning (in shares) at Dec. 31, 2019 8,531,504            
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) $ 13 7,461         7,474
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) (in shares) 13,111,999            
Deemed dividend in connection with repricing of November 2019 warrants   451         451
Warrant deemed dividend   (451)         (451)
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711)   4,602         4,602
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) (in shares)           5,313  
Beneficial conversion feature in connection with issuance of Series B Convertible preferred stock   1,260         1,260
Preferred stock deemed dividend   (1,260)         (1,260)
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292) $ 4 1,891         1,895
ssuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292) (in shares) 3,837,000            
Issuance of common stock upon conversion of Series A Convertible preferred stock $ 9 (9)          
Issuance of common stock upon conversion of Series A Convertible preferred stock (in shares) 9,321,053         (5,313)  
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221) $ 14 14,770         14,784
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221) (in shares) 14,550,000            
Employee stock purchase plan   2         2
Employee stock purchase plan (in shares) 1,578            
Stock-based compensation   360         360
Foreign currency translation gain     (14)       (14)
Net loss       (7,273)     (7,273)
Balance, at end at Mar. 31, 2020 $ 49 $ 255,601 $ (60) $ (224,343)     $ 31,247
Balance, at end (in shares) at Mar. 31, 2020 49,353,134